What evidence the EU requires for drugs and biologics
An application for a marketing authorisation in the European Union must present the results of three sets of studies: pharmaceutical tests that are physico-chemical, biological or microbiological, pre-clinical toxicological and pharmacological tests, and clinical trials. That requirement sits in Article 8(3)(i) of Directive 2001/83/EC and applies to a full application, subject to the derogations in Articles 10 and 10a.1 Articles 10 and 10a then set out the routes on which an applicant relies on a reference product or on published literature in place of its own pre-clinical and clinical results. The route chosen determines what has to be proven and with what kind of study.
The full application under Article 8(3)
Article 8(1) requires the application to go to the competent authority of the Member State concerned, regardless of the procedure established by Regulation (EEC) No 2309/93.1 Article 8(2) restricts the grant of an authorisation to an applicant established in the Community.1 Article 8(2a) allows the competent authorities of the United Kingdom in respect of Northern Ireland to authorise applicants established in other parts of the United Kingdom. Until 31 December 2024 Article 8(2b) allowed the competent authorities of Cyprus, Ireland and Malta to grant marketing authorisations under the mutual recognition or the decentralised procedure to holders established in parts of the United Kingdom other than Northern Ireland. Those authorisations cease to be valid at the latest on 31 December 2026.1
The particulars and documents listed in Article 8(3) are submitted in accordance with Annex I. They include the name or corporate name and permanent address of the applicant and where applicable of the manufacturer. They also include the name of the product and the qualitative and quantitative particulars of all constituents. The constituents are given with the international non-proprietary name recommended by the WHO where one exists, or with the relevant chemical name.1 The dossier also carries the following.1
- a description of the manufacturing method
- the therapeutic indications, contra-indications and adverse reactions
- the posology and pharmaceutical form
- the method and route of administration
- the expected shelf life
Three further items round out the quality and manufacturing side of the dossier. Article 8(3)(h) requires a description of the control methods employed by the manufacturer. Article 8(3)(ha) requires a written confirmation that the manufacturer of the medicinal product has verified the compliance of the active substance manufacturer with the principles and guidelines of good manufacturing practice, by conducting audits in accordance with point (f) of Article 46.1 That confirmation must reference the date of the audit and declare that its outcome confirms compliance.1 Article 8(3)(k) requires a document showing that the manufacturer is authorised in his own country to produce medicinal products.1
The three sets of test results and their summaries
Article 8(3)(i) names the three categories of result in full. The pharmaceutical tests cover the physico-chemical, biological or microbiological properties of the product. The pre-clinical tests are the toxicological and pharmacological studies. The third category is the clinical trials themselves.1 The documents and information concerning these results must be accompanied by detailed summaries in accordance with Article 12.1
Where any clinical trial was carried out outside the European Union, Article 8(3)(ib) requires a statement to the effect that it meets the ethical requirements of Directive 2001/20/EC.1 Article 8(3)(ca) adds an evaluation of the potential environmental risks posed by the product. That impact is assessed and specific arrangements to limit it are envisaged on a case-by-case basis.1 Article 8(3)(g) requires the reasons for any precautionary and safety measures for storage, administration and waste disposal, with an indication of potential environmental risks.1
Safety system evidence submitted with the dossier
Alongside study results, the applicant must document the system that will handle safety after authorisation. Article 8(3)(ia) requires a summary of the applicant’s pharmacovigilance system. That summary includes proof that a qualified person responsible for pharmacovigilance is at the applicant’s disposal, the Member States in which that person resides and works, and that person’s contact details.1 It also includes a statement signed by the applicant that it has the necessary means to fulfil the tasks and responsibilities listed in Title IX, and a reference to the location where the pharmacovigilance system master file is kept.1
Article 8(3)(iaa) requires the risk management plan describing the risk management system the applicant will introduce, together with a summary of that plan. The system must be proportionate to the identified risks and the potential risks of the product, and to the need for post-authorisation safety data.1 The information in the first subparagraph of Article 8(3) is updated where and when appropriate.1
Product information and prior regulatory history
Article 8(3)(j) requires a summary of the product characteristics in accordance with Article 11. It also requires a mock-up of the outer packaging containing the details provided for in Article 54, a mock-up of the immediate packaging containing the details provided for in Article 55, and a package leaflet in accordance with Article 59.1
Article 8(3)(l) requires copies of the regulatory history of the product elsewhere. That covers any authorisation obtained in another Member State or in a third country, a summary of the safety data including data from periodic safety update reports where available, and suspected adverse reactions reports. A list of the Member States where an application is under examination accompanies these copies.1 Details of any decision to refuse authorisation, whether in the Union or in a third country, must be supplied with the reasons for that decision.1 Where the product carries an orphan designation under Regulation (EC) No 141/2000, Article 8(3)(m) requires a copy of the designation with a copy of the relevant Agency opinion.1
Generic applications under Article 10(1)
Article 10(1) relieves the applicant of the obligation in Article 8(3)(i) to provide pre-clinical and clinical results where it demonstrates that the product is a generic of a reference medicinal product. The reference product must be or have been authorised under Article 6 for not less than eight years in a Member State or in the Community.1 A generic authorised on this basis is placed on the market only after ten years have elapsed from the initial authorisation of the reference product.1 That ten-year period extends to a maximum of eleven years where the holder obtains, during the first eight of those years, an authorisation for one or more new therapeutic indications held during scientific evaluation to bring a significant clinical benefit over existing therapies.1
The reference product need not have been authorised in the Member State where the generic application is made. In that case the applicant names in the application form the Member State where the reference product is or has been authorised.1 On request, the competent authority of that other Member State transmits within one month a confirmation of the authorisation together with the full composition of the reference product.1
Article 10(2)(b) sets the evidential test for generic status. The product must have the same qualitative and quantitative composition in active substances and the same pharmaceutical form as the reference product, and its bioequivalence must be demonstrated by appropriate bioavailability studies.1 The following different forms of an active substance count as the same active substance, unless they differ significantly in safety or efficacy properties.
- salts
- esters
- ethers
- isomers
- mixtures of isomers
- complexes
- derivatives
Where they do differ significantly, the applicant must supply additional information proving the safety or efficacy of the various salts, esters or derivatives.1 The various immediate-release oral pharmaceutical forms count as one and the same pharmaceutical form. Bioavailability studies may be dispensed with where the applicant demonstrates that the generic meets the relevant criteria defined in the appropriate detailed guidelines.1
Hybrid applications under Article 10(3)
Article 10(3) governs the case where the product falls outside the generic definition in Article 10(2)(b), where bioequivalence cannot be demonstrated through bioavailability studies, or where the active substances, therapeutic indications, strength, pharmaceutical form or route of administration change relative to the reference product. In each of those situations the results of the appropriate pre-clinical tests or clinical trials must be provided.1 The scope of that evidence follows from the nature of the difference being claimed.
Similar biological medicinal products under Article 10(4)
Article 10(4) is the route for a biological medicinal product similar to a reference biological product that fails the generic definition. The typical reasons are differences relating to raw materials and differences in manufacturing processes between the two products.1 The applicant must provide the results of appropriate pre-clinical tests or clinical trials relating to those conditions. The type and quantity of supplementary data must comply with the relevant criteria in Annex I and the related detailed guidelines.1 Results of other tests and trials from the reference product’s dossier are not to be provided.1 Article 10(4) sits in the same directive as the generic route, and the eight-year and ten-year periods appear in Article 10(1).1
Well-established use under Article 10a
Article 10a offers a second derogation from Article 8(3)(i). The applicant is relieved of the obligation to provide pre-clinical or clinical results where it demonstrates that the active substances have been in well-established medicinal use within the Community for at least ten years, with recognised efficacy and an acceptable level of safety in terms of the conditions set out in Annex I.1 In that event the test and trial results are replaced by appropriate scientific literature.1 The evidence here is therefore documentary and bibliographic, and the burden lies on showing the duration of use and the efficacy and safety record.
One year of data exclusivity for a new indication
Article 10(5) adds a separate protection. Where an application is made for a new indication for a well-established substance, a non-cumulative period of one year of data exclusivity is granted.1 The condition is that significant pre-clinical or clinical studies were carried out in relation to that new indication.1
Studies conducted to prepare a derogation application
Article 10(6) addresses the intellectual property position of the studies themselves. Conducting the necessary studies and trials for the purposes of Article 10(1), (2), (3) and (4), together with the consequential practical requirements, is not regarded as contrary to patent rights or to supplementary protection certificates for medicinal products.1 This provision applies to the generic, hybrid and similar biological routes alike.
Questions people also ask
What studies must a full marketing authorisation application in the EU contain?
Article 8(3)(i) of Directive 2001/83/EC requires the results of pharmaceutical tests that are physico-chemical, biological or microbiological, pre-clinical toxicological and pharmacological tests, and clinical trials. These results are submitted in accordance with Annex I and are accompanied by detailed summaries in accordance with Article 12.1
How long must a reference medicinal product have been authorised before a generic application can rely on it?
Article 10(1) requires the reference product to have been authorised under Article 6 for not less than eight years in a Member State or in the Community. The generic may then be authorised, but it is placed on the market only after ten years have elapsed from the initial authorisation of the reference product.1
When does the ten-year market protection period become eleven years?
The ten-year period extends to a maximum of eleven years where the marketing authorisation holder obtains, during the first eight of those ten years, an authorisation for one or more new therapeutic indications. Those indications must be held, during the scientific evaluation preceding their authorisation, to bring a significant clinical benefit in comparison with existing therapies.1
What distinguishes a generic application from a hybrid application?
A generic application under Article 10(1) rests on identical qualitative and quantitative composition in active substances, the same pharmaceutical form and demonstrated bioequivalence. Article 10(3) applies where the product falls outside that definition, where bioequivalence cannot be demonstrated through bioavailability studies, or where the active substance, indications, strength, form or route of administration differ. In those cases the results of the appropriate pre-clinical tests or clinical trials must be supplied.1
What extra data does a similar biological medicinal product have to provide?
Under Article 10(4) the applicant provides the results of appropriate pre-clinical tests or clinical trials relating to the differences in raw materials or manufacturing processes that take the product outside the generic definition. The type and quantity of that supplementary data must comply with the criteria in Annex I and the related detailed guidelines.1
Can published literature replace pre-clinical and clinical study reports?
Article 10a allows appropriate scientific literature to replace the test and trial results where the applicant demonstrates that the active substances have been in well-established medicinal use within the Community for at least ten years. The use must show recognised efficacy and an acceptable level of safety in terms of the conditions set out in Annex I.1
Footnotes
-
Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use. Consolidated version of 2025-01-01. https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:02001L0083-20250101 ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9 ↩10 ↩11 ↩12 ↩13 ↩14 ↩15 ↩16 ↩17 ↩18 ↩19 ↩20 ↩21 ↩22 ↩23 ↩24 ↩25 ↩26 ↩27 ↩28 ↩29 ↩30 ↩31 ↩32 ↩33 ↩34 ↩35 ↩36 ↩37 ↩38 ↩39 ↩40 ↩41 ↩42 ↩43 ↩44 ↩45 ↩46
Pothos builds longitudinal molecular profiles of individuals: whole-genome sequencing, single-cell RNA sequencing, and plasma proteomics, delivered as a detailed report, every data file, and stored cells. Build your profile.